Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RAP2A
REST API REST API
Homo sapiens
RAP2A is differentially expressed in 327 experiments: 130 organism parts: liver, brain, ... (128 more);, 179 disease states: normal, control, ... (177 more);, 102 cell types 420 cell lines 54 compound treatments and 79 other conditions.
Synonyms RAP2, K-REV
Orthologs ENSCING00000001232 (Ciona intestinalis)   RSR1 (Saccharomyces cerevisiae)   RAP2A (Bos taurus)   RAP2A (Gallus gallus)   Rap2a (Mus musculus)   Q78P65_RAT (Rattus norvegicus)   RAP2A (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, regulation of JNK cascade, actin cytoskeleton reorganization, GTPase activity, protein binding, establishment of protein localization, intracellular, membrane, intracellular protein transport, GTP catabolic process, GTP binding, recycling endosome, small GTPase mediated signal transduction, negative regulation of cell migration, nucleotide binding, nucleocytoplasmic transport, regulation of dendrite morphogenesis, signal transduction, protein transport, recycling endosome membrane, cellular protein localization, Rap protein signal transduction, positive regulation of protein autophosphorylation
InterPro Term Ran_GTPase, MIRO-like, ProtSyn_GTP-bd, Small_GTPase, Small_GTP-bd_dom, Small_GTPase_ARF/SAR, Small_GTPase_Ras, Small_GTPase_Rho, Small_GTPase_Rab_type
UniProt Accession P10114, F6U784
Search EB-eye ENSG00000125249
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
HT1080
2
E-MTAB-37, E-GEOD-20089
BT474
2
E-MEXP-440, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MDA-MB-231
2
E-TABM-420, E-MTAB-62
414 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
neutrophil
1
2
E-GEOD-12662, E-GEOD-3982, E-GEOD-995
macrophage
1
2
E-GEOD-22373, E-GEOD-360, E-GEOD-3982
wild_type
1
E-GEOD-20193
fibroblast
1
E-GEOD-26672
M2 macrophage
1
E-GEOD-5099
adrenal neuroblast
1
E-MEXP-669
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, ... (63 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-GEOD-4412, E-GEOD-6014
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
prostate cancer
2
E-MTAB-62, E-GEOD-6919
prostate carcinoma
2
E-MEXP-2034, E-GEOD-7307
lung adenocarcinoma
1
2
E-MTAB-62, E-GEOD-2514, E-MTAB-37
cervical carcinoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-5823
173 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-697, ... (33 experiments)

Factor Value U/D Experiments
none
4
10
E-MEXP-1958, E-TABM-782, E-MEXP-1230, E-GEOD-5824, E-GEOD-412, ... (14 experiments)
glutamine
2
E-MEXP-1335, E-MEXP-941
lipopolysaccharide
1
2
E-MEXP-1958, E-GEOD-3720, E-TABM-868
saline
1
E-GEOD-3026
potassium dichromate
1
E-GEOD-6907
phoshate buffered saline
1
E-GEOD-3720
48 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
37
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, E-GEOD-16363, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-3140, E-GEOD-6236, E-GEOD-4667 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-GEOD-2509, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-6207, E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-TABM-127, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-2634, E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922, E-TABM-147

Tumor size
studied in E-GEOD-6532

Processing time: 0.459 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM